Compare PGY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | PRAX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 9.6B |
| IPO Year | 2021 | 2020 |
| Metric | PGY | PRAX |
|---|---|---|
| Price | $20.91 | $313.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $34.50 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 2.0M | 297.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.43 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $1,301,360,000.00 | N/A |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $14.39 | $7,758.26 |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | ★ 26.07 | N/A |
| 52 Week Low | $10.40 | $40.12 |
| 52 Week High | $44.99 | $392.70 |
| Indicator | PGY | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 40.45 |
| Support Level | $20.50 | $290.53 |
| Resistance Level | $23.45 | $331.21 |
| Average True Range (ATR) | 1.14 | 14.90 |
| MACD | -0.29 | -5.02 |
| Stochastic Oscillator | 44.98 | 2.94 |
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.